The historical rank and industry rank for Corbus Pharmaceuticals Holdings's Equity-to-Asset or its related term are showing as below:
CRBP'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.24 Med: 0.54 Max: 0.89
Current: -0.24
During the past 11 years, the highest Equity to Asset Ratio of Corbus Pharmaceuticals Holdings was 0.89. The lowest was -0.24. And the median was 0.54.
CRBP's Equity-to-Asset is ranked worse than 86.9% of 1565
companies
in the Biotechnology industry
Industry Median: 0.67
vs CRBP: -0.24
Corbus Pharmaceuticals Holdings Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Corbus Pharmaceuticals Holdings's Equity-to-Asset
For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corbus Pharmaceuticals Holdings's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Corbus Pharmaceuticals Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Corbus Pharmaceuticals Holdings Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Business Description
Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRBP has been successfully added to your 